Investigating how a specific molecule affects immune-related side effects in cancer treatment
Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy
This study is looking at a new molecule called LPC 18:2 to see how it might help reduce side effects from cancer immunotherapy and improve the immune system's response in patients with different types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | La Jolla Institute for Immunology NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10872314 on NIH RePORTER |
What this research studies
This research focuses on understanding how a novel small molecule, LPC 18:2, can modulate immune-related adverse events (irAEs) that occur during cancer immunotherapy. By studying patients with various types of cancer who are undergoing immune checkpoint blockade therapy, the research aims to identify the relationship between LPC 18:2 levels and the occurrence of irAEs. The study will also explore how this molecule may influence tumor regression and the immune system's response. Patients will be monitored for their immune responses and any side effects experienced during treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with late-stage cancers such as melanoma, non-small cell lung cancer, and head and neck cancer who are receiving immune checkpoint blockade therapies.
Not a fit: Patients who are not undergoing immune checkpoint blockade therapy or those with early-stage cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or managing harmful side effects of cancer immunotherapy, improving patient safety and treatment outcomes.
How similar studies have performed: Previous research has shown promise in using molecular modulators to address immune-related side effects in cancer therapies, but this specific approach with LPC 18:2 is novel.
Where this research is happening
La Jolla, United States
- La Jolla Institute for Immunology — La Jolla, United States (Active)
Researchers
- Principal investigator: Sharma, Sonia — La Jolla Institute for Immunology
- Study coordinator: Sharma, Sonia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.